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Post-transcriptional regulationCellular iron homeostasis is maintained by iron regulatory proteins 1 and 2 (IRP1 and IRP2). IRPs bind to
iron-responsive elements (IREs) located in the untranslated regions of mRNAs encoding protein involved
in iron uptake, storage, utilization and export. Over the past decade, signiﬁcant progress has been made
in understanding how IRPs are regulated by iron-dependent and iron-independent mechanisms and the
pathological consequences of IRP2 deﬁciency in mice. The identiﬁcation of novel IREs involved in diverse
cellular pathways has revealed that the IRP–IRE network extends to processes other than iron homeostasis.
A mechanistic understanding of IRP regulation will likely yield important insights into the basis of disorders
of iron metabolism. This article is part of a Special Issue entitled: Cell Biology of Metals.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Iron is required by most organisms as it serves as a prosthetic group
for proteins involved in central cellular processes, including respiration,
DNA synthesis and oxygen transport. In excess, cellular iron catalyzes
the generation of free radicals that damage protein, DNA and lipids,
whereas cellular irondeﬁciency impairs cellular proliferation. In humans,
with the inherited diseases hemochromatosis, excess cellular iron can
result in cirrhosis, cardiomyopathy and diabetes mellitus (reviewed
in [1]). Excess iron content in the brain is associated with several
inherited neurodegenerative diseases, including neurodegeneration
with brain iron accumulation (NBIA) and Friedreich's ataxia (FA), as
well as common neurodegenerative disorders such as Parkinson's
and Alzheimer's diseases (reviewed in [1–3]). On the other hand,
iron deﬁciency affects billions of people worldwide, and results in
cognitive defects in children and anemia in adults. Cellular iron content
must therefore be maintained within a narrow range to avoid the
adverse consequences of iron deﬁciency or excess. Maintenance
of cellular iron homeostasis is accomplished by the coordinated
regulation of iron uptake, storage and export by iron-regulatory
proteins 1 and 2 (IRP1 and IRP2, also known as ACO1 and IREB2).
This review focuses on advances in IRP regulation of iron metabolismiology of Metals.
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l rights reserved.focusing on the past 6 years. We direct readers to several excellent
reviews on IRPs [4–7] and to chapters in this volume on systematic
iron homeostasis, iron–sulfur (Fe–S) cluster biogenesis, iron trafﬁck-
ing, and SKP1–CUL1–FBXL5 structure and function.
2. Overview of systemic and cellular iron metabolism
2.1. Systemic iron metabolism
Approximately, 1–3 mg of iron is absorbed by humans each day, in
order to replace iron losses in the urine, sweat and from desquamated
enterocytes. As mammals lack a regulated physiological mechanism
for iron excretion, intestinal iron absorption is a highly regulated pro-
cess. Dietary non-heme ferric iron is absorbedby enterocytes by divalent
metal transporter 1 (SLC11A2, also known as DMT1 and NRAMP2) after
reduction by membrane bound ferrireductases (such as duodenal cyto-
chrome b (CYBRD1, also known as DCYTB)) (Fig. 1). Heme iron is also
taken up by enterocytes by an undeﬁned mechanism. Cellular iron is
translocated through the enterocyte and is exported into the circulation
by the basolateral exporter ferroportin (SLC40A1). Iron export is depen-
dent on the oxidation of iron by the membrane bound multicopper
oxidase hephaestin enabling it to bind to plasma transferrin (Tf).
Diferric Tf (Tf-Fe(III) is the major form of iron for most cells with ery-
throid precursors being the major user as iron is required for heme syn-
thesis. Tf-Fe(III) binds to cell surface transferrin receptor 1 (TFRC, also
known as TfR1) followed by internalization of the Tf-Fe(III)–TfR1 com-
plex by clathrin-mediated endocytosis. On acidiﬁcation of the endosome,
ferric iron is released from Tf and reduced by STEAP3, and exported into
Fig. 1. Control of mammalian cellular iron homeostasis by the IRE–IRP regulatory network. A generic mammalian cell depicting roles of proteins encoded by IRE-containing mRNAs
(red lettering). Transferrin bound to two iron atoms (Tf-[Fe(III)2) binds to TfR1 on the cell surface where the Tf-[Fe(III)2–TfR1 complex is endocytosed. Acidiﬁcation of the endosome
causes the release of Fe(III) (red balls) from Tf where it is reduced to Fe(II) (orange balls) by the STEAP3 oxidoreductase before export by DMT1 (divalent metal transporter 1).
ApoTf/TfR1 complex is returned to the cell surface where it dissociates and initiates another round of iron uptake. Tf-bound iron is taken up by most cells, but it is especially im-
portant in erythroid precursors where it is the primary source of iron for heme synthesis. DMT1 is also localized on the apical membrane of duodenal enterocytes where it trans-
ports Fe(II) after reduction by membrane reductases, such as DCYTB. Iron taken up by either TfR1 or DMT1 enters a cytosolic free labile iron pool thought to consist of Fe(II) bound
to small molecular weight molecules. IRPs sense iron in this pool and regulate the translation of 5′ IRE-containing mRNAs (H-ferritin and L-ferritin, eALAS (erythroid
aminolevulinate synthase), mitochondrial (m)-aconitase and ferroportin) or the stability of 3′ IRE-containing mRNAs (TfR1 and DMT1). eALAS serves as the rate-limiting enzyme
in heme synthesis in erythroid precursors. Mitochondrial aconitase is an enzyme in the TCA cycle that requires a [4Fe–4S] cluster for activity. Iron that is not utilized or stored in
ferritin is exported by ferroportin. Export of iron from cells is coupled to the oxidation of iron by membrane-bound hephaestin or serum multicopper oxidase ceruloplasmin (CP).
Modiﬁed from Wallander et al. [4].
Fig. 2. IRPs regulate translation and stability of IRE-containing mRNAs. IRPs bind to IREs
located in either the 5′ or 3′ untranslated regions of speciﬁc mRNAs. When iron is limited,
IRPs bindwith high afﬁnity to 5′ IREmRNAs and repress translation, and to theﬁve 3′ IREs
in TfR1mRNA and to the single IRE in DMT1mRNA and stabilize thesemRNAs.When iron
is abundant, IRPs do not bind IREs, resulting in the translation of 5′ IRE-containingmRNAs
and degradation of TfR1 mRNA. Iron mediates the conversion of the IRP1 RNA binding
form into the [4Fe–4S] cluster c-aconitase form and the ubiquitination and targeted
proteasomal degradation IRP2 by FBXL5 E3 ligase. IRE-containing mRNAs indicated are
those that have been shown to be functional in vivo.
Modiﬁed fromWallander et al. [4].
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containing proteins and by the mitochondria for biosynthesis of Fe–S
clusters and heme. When body iron stores and erythropoiesis are ade-
quate, iron export from enterocytes is reduced by hepcidin-mediated
internalization and degradation of ferroportin, and instead iron is stored
in ferritin. Iron in ferritin is lost after 3 days by desquamation of intestinal
cells.
The small amount of iron (1–3 mg) absorbed by humans each
day represents only a fraction of the total body iron, and most of
the circulating iron comes from the recycling of heme from senescent
erythrocytes by reticuloendothelial macrophages. The iron released
from heme is exported into the circulation by ferroportin where it
binds to apoTf for delivery to bone marrow for hemoglobin synthesis.
Elevated hepatic iron stores and inﬂammation increase hepcidin
production, which mediates ferroportin degradation in intestinal cells
and in reticuloendothelial macrophages, leading to reduced plasma
iron levels.
2.2. IRPs are the principal cellular iron regulators in vertebrates
Maintaining cellular iron content requires precise mechanisms for
regulating its uptake, storage and export. IRP1 and IRP2 are the principal
regulators of cellular iron homeostasis in vertebrates. IRPs are cytosolic
proteins that bind to iron-responsive elements (IREs) in the 5′ or 3′
untranslated regions of mRNAs encoding proteins involved in iron
uptake (TfR1, DMT1), sequestration (H‐ferritin subunit (FTH1) and
L‐ferritin subunit (FTL)) and export (ferroportin) (Fig. 2). When
cells are iron deﬁcient, IRPs bind to 5′ IREs in ferritin and ferroportin
mRNAs with high afﬁnity to repress translation, and to 3′ IREs in TfR1
mRNA to block its degradation. When iron is in excess, IRPs do not
bind to IREs, increasing synthesis of ferritin and ferroportin, while
promoting the degradation of TfR1 mRNA. The coordinated regulation
of iron uptake, storage and export by the IRPs ensures that cells acquire
adequate iron for their needs without reaching toxic levels.
IRPs also regulate other mRNAs that contain 5′ IREs, including
mitochondrial aconitase (ACO2, also known as m-acon, tricarboxylic
acid cycle (TCA)), erythroid aminolevulinate synthase (ALAS2, also
known as eALAS, heme biosynthesis), hypoxia-inducible transcription
factor-2α (EPAS1 also known as HIF-2α, hypoxia adaptation) andamyloid beta precursor protein (APP, Alzheimer's disease), and 3′ IREs,
including DMT1 (metal transport), CDC14A (mitotic phosphatase),
CDC42‐binding protein kinase α (also known as MRCKα, cytoskeletal
dynamics) and hydroxyacid oxidase 1 (HAO1, peroxisomal enzyme)
[8–17]. More recently, a transcriptome-wide approach was utilized to
identify 35 novel putative IRE-containing mRNAs, some of which have
exclusivity for IRP1 or IRP2 [18]. While these mRNAs each contain an
IRE, the roles of many of these IREs in vivo remain to be determined.
The presence of IREs in a variety of mRNAs indicates that IRP regulation
extends to processes other than iron homeostasis.
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Although IRP1 and IRP2 share approximately 64% identity, bind
RNA and are regulated by iron, they differ in several ways. First, IRP1
is a bifunctional protein serving either as a high afﬁnity IRE binding
protein in its apoprotein form or the cytosolic isoform of the iron–
sulfur (Fe–S) enzyme aconitase (c-acon) (Fig. 3). Formation and loss
of the [4Fe–4S] cluster regulates RNA binding and provides unique
links between IRP1 and cellular Fe–S cluster biogenesis. Second, IRP1
has distinctive roles in the adaptive response to oxygen availability as
well as in sensing reactive oxygen species (ROS) or reactive nitrogen
species (RNS). Third, IRP1 is controlled by multiple iron-dependent
mechanisms, including targeted protein degradation to limit accumula-
tion of the RNA binding form of IRP1 [19]. Fourth, phosphorylation of
IRP1 at serine 138 dictates the mechanism of its regulation by iron.
Unlike IRP1, IRP2 lacks a [4Fe–4S] cluster and aconitase activity, and
functions as an RNA binding protein. IRP2 is primarily regulated by
iron-mediated degradation. Thus, IRP1 responds to iron-dependent
and iron-independent signals that control its function throughmultiple
mechanisms in order to maintain IRE-binding activity within a range
that permits the optimal maintenance of cellular iron homeostasis.
3.1. Regulation of IRP1 RNA binding activity by the 4Fe–4S cluster
The key role of the [4Fe–4S] cluster in IRP1 in controlling RNA
binding activity provides ameans for linking cellular pathways involved
in formation of these cofactors to cellular iron status. In recent years,
many studies have focused onunraveling themechanismand pathways
of Fe–S biogenesis in model organisms and their dysfunction in human
disease [20–23] [see also Lill et al. in this volume]. In brief, the evidence
indicates that the major pathway for biogenesis of Fe–S clusters and
their insertion into cytosolic proteins, such as IRP1, ﬁrst involves
targeting of iron to the mitochondria where it is imported through the
action of mitoferrin [24] [see also Paw et al. in this volume]. A transient
Fe–S cluster is formed on the scaffold protein ISCU through the action of
iron, the iron binding protein frataxin and sulﬁde derived from cysteine
via the cysteine desulfurase NFS1 and its partner ISD11 [25–30]. The
Fe–S cluster on ISCU, or in some cases other scaffold proteins [31], isFig. 3. Iron-dependent and iron-independent mechanisms for regulating IRP1. IRP1 can
be regulated through mechanisms dependent or independent of the [4Fe–4S] cluster. In
the cluster-dependent pathway, IRP1 has dual roles either as a high afﬁnity IRE-binding
protein when devoid of the [4Fe–4S] cluster or as a c-aconitase when the [4Fe–4S] cluster
is assembled. The c-aconitase formdoes not bind RNA. The [4Fe–4S] cluster is accessible to
lowmolecular cluster perturbants, including reactive oxygen species (ROS), such as O2•−,
H2O2 or reactive nitrogen species (RNS), such as NO• or ONOO−. Hypoxia stabilizes
the c-aconitase form by reducing the level of oxygen or ROS. IRP1 can be phosphorylated
at S138. IRP1 phosphomimetic mutants indicate that the Fe–S cluster can be assembled
and the protein exhibits aconitase activity; however, the Fe–S cluster is more sensitive
to disruption by oxygen and hydrogen peroxide. Iron stimulates the FBXL5-mediated
degradation of IRP1 S138 phosphomimetic mutants and non-phosphorylated IRP1 when
Fe–S cluster biogenesis is impaired.
Modiﬁed fromWallander et al. [4].donated to apoprotein targetswith the assistance of protein chaperones
(e.g. HSCB in humans) and electron donors (e.g. FDX, ferredoxin) [21].
Activities of the mitochondrial Fe–S cluster biogenesis machinery
alongwith the exportmachinery components (e.g. ABCB7) are required
for activation of the cytosolic Fe–S cluster assembly (CIA) pathway.
Genetic approaches using IRP1 expressed in yeast led to discovery
of the ﬁrst CIA factor, Cfd1 [32]. Additional elegant studies primarily
in yeast led to identiﬁcation of Nbp35 that together with Cfd1 forms the
initial Fe–S scaffold for cytosolic cluster formationwith the assistance of
DRE2 and TAH18 [30,32–36]. Transfer of the labile cluster from Cfd1/
Nbp35 to some apoprotein targets requires the Nar1/Cia1 heteromer
while for others Nbp35 sufﬁces (reviewed in [22]). Interestingly, recent
studies have begun to identify “speciﬁcity factors” that target speciﬁc
apoFe–S proteins (e.g. complex 1) [37,38]. Whether or not separate
pathways for Fe–S cluster biogenesis exist for sensory and regulatory
roles of Fe–S proteins in mammalian cells, such as IRP1, remains to be
determined.
Primarily through the use of RNAi-based knockdown approaches,
the activity of the Fe–S biogenesis pathways have been shown to
inﬂuence cellular iron sensing and distribution in mammalian cells.
Disruption of components of the mitochondrial Fe–S biogenesis
pathway, including the cysteine desulfurase NFS1 and its partner ISD11
[25,39], the Fe–S scaffolds ISCU [40] and ISCA [41], the iron binding
protein frataxin [27,42], glutaredoxin 5 [43], protein chaperone
HSC20 [44,45] and electron donors ferredoxins 1 and 2 [39,46], impairs
the activity of both mitochondrial, cytosolic, and presumably nuclear
Fe–S proteins in mammalian cells. The ensuing reduction in c-acon
activity is reﬂected in IRP1 activation that is associatedwith an increase
in TfR1 and reduction in ferritin expression. That IRP2 is stabilized
suggests a general cytosolic iron deﬁciency [39,43,44,47,48]. While
the increase in TfR1 and repression of ferritin induced by IRP activation
may reﬂect a compensatory mechanism to combat cytosolic iron
deﬁciency, failure to prevent further inappropriate iron accumulation
in the face of excess iron reﬂects an inability to downregulate IRP activ-
ity that could be cytotoxic [40]. There is also evidence of cellular iron
maldistributionwith abnormal cellular iron deposits andmitochondrial
overload coupled with cytosolic iron deﬁciency when mitochondrial
Fe–S biogenesis is impaired [40,43,47]. Similar changes have been ob-
served in yeast [49–53]. While these studies conﬁrm the concept that
cytosolic Fe–S cluster biogenesis is dependent on active mitochondrial
cluster formation in mammalian cells, they also demonstrate that the
impact of impaired mitochondrial Fe–S biogenesis may in part involve
indirect effects on IRPs or IRP targets. Future studies should address
questions concerning what pathways of Fe–S cluster biogenesis are
sensed by IRP and whether trafﬁcking of iron through mitochondria is
an obligate process through which IRP senses iron.
The impact of impaired cytosolic Fe–S cluster biogenesis on IRP1 has
also been examined [54–58]. Reduction of NUBP1 andNAR1 speciﬁcally
impairs cytosolic Fe–S proteins, including c-acon and others [56–58].
Concomitant with this is the activation of IRP1 along with an increase
in TfR1 and a reduction in ferritin expression. Interestingly, IRP2 is not
affected suggesting that the response of IRP2 observedwhenmitochon-
drial Fe–S biogenesis is impaired is a secondary response to the maldis-
tribution of cellular iron. Thus, as is the case when the cytosolic Fe–S
cluster biogenesis system is inhibited in yeast, inhibition of the cognate
proteins in mammalian cells has a selective impact on cytosolic Fe–S
proteins. The ﬁnding that IRP2 is stabilized in ABCB7-deﬁcientmamma-
lian cells may reﬂect a feedback effect on mitochondrial Fe–S cluster
formation or iron metabolism [55]. Deletion of the yeast homolog of
ABCB7, Atm1p, also leads to an abnormal distribution of iron [51].
Taken together, these studies suggest that unlike IRP1, IRP2 does not
sense the ﬂux of iron through the cytosolic Fe–S biogenesis pathway.
Investigations of the etiology of FA provide the most clearly
understood example linking a human disease of Fe–S cluster biogenesis
and alterations in IRP function (reviewed in [59–61]). FA is the most
common inherited ataxia in humans. It is primarily caused by formation
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expression of this small acidicmitochondrial protein althoughmissense
mutations of frataxin are also a cause. Frataxin binds to a complex
containing the Fe–S scaffold protein ISCU and the cysteine desulfurase
NFS1 and its partner ISD11, and in this process is believed to function
as an iron chaperone [27–29,62]. One study reported that a small por-
tion of frataxin also functions in the cytosol where it interacts with
IRP1 and facilitates conversion to c-acon [42]. At the cellular level, FA
is characterized by a loss of activities of mitochondrial, cytosolic, and
presumably nuclear Fe–S proteins. Similar to what has been observed
with the knockdown of other participants inmitochondrial Fe–S cluster
biogenesis pathway, FA is associated with mitochondrial iron overload
and signs of cytosolic iron deﬁciency [27,63,64]. Both IRPs are activated,
and this is associated with a reduction in ferritin and increase in TfR1
expression. Furthermore, expression of the iron exporter ferroportin is
reduced further contributing to the abnormal iron distribution, and
presumably to oxidative stress observed in FA [64]. Interestingly,
frataxin deﬁciency is associated with a reduction of other components
of the mitochondrial Fe–S cluster machinery, including ISCU and NFS1,
along with defects in heme synthetic enzymes [64]. The fact that
frataxin expression is itself reduced in iron deﬁciency suggests that
the induction of cytosolic iron deﬁciency due to impairedmitochondrial
Fe–S cluster biogenesis could be ampliﬁed by a downstream impact of
reduced frataxin expression [27]. An interesting area for further investi-
gation concerns the extent towhich enhanced accumulation of IRE RNA
binding activity, especially that provided by the large latent pool of IRP1
RNA binding activity in the form of c-acon, coupled with impaired
ability to down-regulate IRP due to inhibition of the iron-dependent
SKP1–CUL1–FBXL5 (S-phase kinase-associated protein 1-Cullin 1-F-
box-leucine rich repeat protein 5) E3 ubiquitin ligase further exacerbates
disease etiology. This issue likely has relevance to numerous diseases
of Fe–S cluster biogenesis (reviewed in [46,59]).
3.2. Fe–S cluster disassembly in c-acon facilitates sensing reactive oxygen
and nitrogen species
The discovery that IRP1 RNA binding activity could be generated
from c-acon raised a key issue of how, and under what conditions,
could the Fe–S cluster be removed. Iron deﬁciency per se was not
believed to be sufﬁcient to promote loss of the cluster on its own. How-
ever, aconitases have long been known to sense ROS and RNS because
their [4Fe–4S] cluster is solvent accessible and these reactive species
can initiate cluster loss (reviewed in [65]). In fact, for one isoform of
aconitase in Escherichia coli, the ease with which it was inactivated by
superoxide anion appears to function as a feedback mechanism to
modulate an overactive electron transport chain [66]. This only requires
conversion to the [3Fe–4S] cluster species that, in the case of c-acon, is
not sufﬁcient to generate RNA binding activity. A further important
fact is that aconitases differ in their sensitivity to ROS and RNS, where
c-acon is more resistant [67–69]. Thus, although the Fe–S switch
mechanism was accepted as a bonaﬁde means for iron regulation of
IRP1, the mechanistic basis through which it occurred was not clear.
Insight into this problem came from early studies showing that
tumor cell aconitase was a target of NO generated by activated
macrophages (reviewed in [70]). On this basis, a large number of
studies were initiated demonstrating that NO and its reactive product
ONOO− can facilitate conversion of c-acon to IRP1 (reviewed in [71]).
NO also inﬂuenced IRP2, but the mechanism for this regulation and
the impact on iron metabolism was unclear [72,73]. Recent studies
using mice lacking IRP1 or IRP2 have assessed the role of each IRP in
the NO-dependent regulation of macrophage iron metabolism. These
studies demonstrated that IRP1 was solely responsible for alterations
in macrophage iron metabolism in response to NO [74]. Furthermore,
NO-dependent activation of IRP1 could ameliorate abnormal iron
storage in Irp2−/− bone marrow macrophages ex vivo by repressing
ferritin expression. Similarly, activation of IRP1 by the pharmacologicalnitroxide Tempol prevented the neurodegenerative symptoms in
Irp2−/−mice [75]. Tempol is best known as a free radical scavenger;
however, in Irp2−/− mice Tempol appeared to promote cluster loss
from c-acon through the direct action of RNS.
While the ability of NO to activate IRP1 may be necessary for mac-
rophage activation or action, the physiological role of ROS is less clear.
Loss of the Fe–S cluster from aconitases can be initiated by superoxide
leading to the generation of the [3Fe–4S] non-RNA binding form and
H2O2 generates IRP1 from c-acon although the mechanism through
which this occurs is not clear (reviewed in [76,77]). Increased conver-
sion of c-acon to IRP1 by H2O2 may enhance iron uptake while
impairing storage and export, leading to iron overload. However a re-
cent report suggests a mechanism to partially evade IRP action under
these conditions [78]. Perhaps the physiological role of ROS involves
the constant conversion of a small fraction of c-acon into IRP1.
Depending on the cellular iron status, IRP1 could then be converted
back to c-acon or remain in the RNA binding form to regulate IRE-
containing mRNAs. In other words, physiological generation of ROS
may be necessary for iron sensing by IRP1.
An additional, but not necessarily alternative view is that the
sensitivity of c-acon to ROS and RNS can be regulated allowing for the
existence of pools of protein with a stable versus unstable Fe–S cluster.
Previous studies demonstrated that two protein kinase C phosphoryla-
tion sites exist in IRP1, S138 and S711. S138 phosphomimetic mutants
of c-acon are much more oxygen labile compared to the wildtype pro-
tein and are also at least 10-foldmore sensitive to NO in terms of cluster
disassembly [79,80]. Furthermore, these phosphomutants undergo
spontaneous disassembly of the Fe–S cluster even in the absence of a
perturbant [80]. Another study showed that IRP1 activation by H2O2
requires a signaling pathway possibly involving phosphorylation
[81]. Taken together, these studies show that rapid recruitment of
IRE-binding activity can be achieved by cluster perturbants or phos-
phorylation induced alterations in Fe–S cluster stability.3.3. Iron regulation of IRP1 protein degradation
Early studies on themechanismof IRP1 regulation by iron suggested
that protein degradationwas the primarymechanism for inactivation of
RNA binding [82]. With the demonstration that IRP1 is the cytosolic
isoform of aconitase, and that insertion and loss of the [4Fe–4S] cluster
regulated RNA binding, the “Fe–S switch” mechanism was widely
accepted as the dominant mechanism for controlling IRP1 RNA binding
activity [83]. This view was further advanced by the observation that
total levels of IRP1/c-acon protein did not change as a function of iron
status. Inmany cases, however, the c-acon pool is in vast excess relative
to IRP1 [84,85]. Thus, the much larger and more stable c-acon pool
would mask iron-dependent changes in abundance of IRP1. Liver pro-
vides a case in point as c-acon exceeds IRP1 by more than 100-fold.
Severe dietary iron deﬁciency results in an increase of IRP1 RNAbinding
activity of no more than 4-fold, indicating that a small portion of the c-
acon pool was recruited [84]. Hence, iron-mediated degradation of IRP1
would not be routinely observed using immunoblots. Some evidence
indicated that IRP1 could be regulated through protein degradation
during iron overload or through phosphorylation [86,87]. The role of
protein degradation in controlling IRP1 was examined anew using
models where the Fe–S switch was disrupted either by mutation of
cluster-ligating cysteines or through genetic manipulation of Fe–S clus-
ter assembly or disassembly [54,88]. In this manner, regulation of IRP1
can be examined without c-acon. Under these conditions, IRP1 stability
was clearly iron-regulated, and led to the view that iron-mediated IRP1
degradation was a compensatory mechanism to prevent excess RNA
binding activity when the Fe–S cluster switch mechanism is not active,
which can be lethal [19,54]. The relevance of this mechanism to IRP1
function was further substantiated with the ﬁnding that the FBXL5 E3
ligase that targets IRP2 for degradation also acts on IRP1 [89–91].
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biogenesis is impaired, IRP1 protein levels dropped signiﬁcantly
[25,41,44,47,48,54–58,92]. Under these conditions, IRP1 protein can be
stabilized by iron chelation, suggesting that the loss of IRP1 is not mere-
ly due to instability of an apoprotein but instead is part of a second iron
dependent mechanism to control accumulation of IRP1 RNA binding
activity [54]. Impaired mitochondrial Fe–S biogenesis leads to cytosolic
iron deﬁciency, presumably reducing FBXL5 activity as evidenced by
increased IRP2 protein levels [23,27,39,44,47,48,55]. The mechanism
by which IRP1 is degraded while IRP2 is stabilized under these condi-
tions remains undetermined. Relative to normal cells, a reduction in
FBXL5 activity in response to impaired mitochondrial Fe–S biogenesis
could lead to increased IRP2 accumulation but still be sufﬁcient to
degrade excess IRP1 arising from an inability to accumulate c-acon.
FBXL5 independent mechanisms may also account for this paradox,
but further studies are required to determine FBXL5 function in re-
sponse to impaired mitochondrial Fe–S cluster biogenesis. Regardless
of themechanism, the extent towhich IRP1 and IRP2 RNAbinding activ-
ity rises to pathological levels when Fe–S cluster formation is impaired
is likely to be inﬂuenced by the abundance of c-acon and the extent to
which FBXL5 is inactivated. These factors will likely be strong predictors
of the extent to which IRP1 and IRP2 RNA binding activity rise to unac-
ceptable levels in pathological states involving impaired Fe–S cluster
formation or accelerated cluster disassembly.
3.4. S138 phosphorylation and the mechanism of IRP1 regulation by iron
The Fe–S switch and protein degradation mechanisms for control-
ling IRP1 function could each have unique uses in modulating iron
metabolism in order to meet cellular needs. Hence, issues such as sen-
sitivity to Fe–S biogenesis activity or the level of ROS or RNS may
meet the distinctive iron requirements of speciﬁc cell types or physi-
ological scenarios. A mechanism that could serve these needs involves
S138 phosphorylation of IRP1 by protein kinase C because it leads to
accumulation of the RNAbinding form [93]. The ﬁnding that S138 phos-
phomimetic mutants of IRP1 could be converted to a form of c-acon
with a highly unstable Fe–S cluster suggested an altered set-point for
iron regulation [79]. Surprisingly, the S138E phosphomutant was still
subjected to iron regulation but as a consequence of iron-stimulated
protein degradation reminiscent of IRP2 regulation [87]. In order to
determine if enhanced oxidative damage of IRP1 as a consequence of
increased Fe–S cluster cycling in IRP1S138E promoted its degradation,
the cluster-ligating cysteine residues were mutated to serine, blocking
cluster insertion in S138E and wildtype IRP1 (IRP1S138E/3C>3S and
IRP13C>3S). While this failed to block iron-dependent degradation of
IRP1S138E, the more surprising result was that the protein level of
IRP13C>3S and another cluster mutant were iron-regulated [54,88].
These observations were conﬁrmed by the subsequent demonstration
that IRP1 is a substrate for the FBXL5 E3 ligase [89,90]. Recent studies
indicate that IRP1S138E can be regulated either by protein degradation
or Fe–S cluster insertion depending on the level of ROS or RNS [80].
These studies suggest that S138 phosphorylation of IRP1 is a mecha-
nism to rapidly increase IRP1 RNA binding activity and to facilitate
formation of a pool of c-acon that is sensitive to cluster perturbants
and cellular iron levels. Coupled with the iron-mediated degradation
of IRP1 by FBXL5, inducible phosphorylation broadens the physiological
scenarios of IRP1 action.
3.5. IRPs and oxygen sensing
The discovery of a functional IRE in the 5′ UTR of the mRNA
encoding HIF-2α suggested new roles for IRPs in the adaptive re-
sponse to hypoxia and iron deﬁciency [10]. A recent study reported
that HIF-2α mRNA is translationally repressed in liver from iron-
deﬁcient rats, and is associated with increased IRP1 and IRP2 activity
[94]. Other studies have provided evidence that the HIF-2α IRE ispreferentially targeted by IRP1 [11,95]. HIF-2α is primarily regulated
by protein stabilization in response to hypoxia and iron deﬁciency
(reviewed in [96,97]). Under these conditions, HIF-2α stimulates eryth-
ropoiesis through activation of erythropoietin (EPO) and intestinal iron
absorption through the activation of DMT1 and ferroportin [98–101],
providing a mechanism to coordinate iron uptake with red cell produc-
tion. IRP-dependent translational regulation of HIF-2αmRNA has been
proposed as a mechanism to reduce EPO production during hypoxia
resulting from impaired erythropoiesis in iron deﬁcient anemia, there-
by ensuring that microcytic hypochromic red blood cells are not
produced [10]. Given the preferential regulation of HIF-2α mRNA by
IRP1, this suggests that under hypoxic iron sufﬁcient conditions IRP1
would exist in its c-acon form, and unable to bind RNA, ensuring that
HIF-2α mRNA is translated and EPO is produced. The signiﬁcance of
the preferential regulation of the HIF-2α IRE by IRP1 requires further
investigation.
3.6. Hierarchical regulation of IRE-containing mRNA
Vertebrate mRNAs containing consensus IREs encode proteins of
widely varying function, from those with a direct role in iron metab-
olism to proteins involved in the regulation of citrate metabolism (m-
acon), cell proliferation, cytoskeletal dynamics (MRCKα), cell cycle
(CDC14A), and in the adaptive responses to hypoxia (HIF-2α). The
broad functional spectrum of proteins encoded by IRE-containing
mRNAs suggests that they are not identically regulated by IRPs. A
comparison of the binding afﬁnity of 5′ IRE-containing mRNAs to
IRP1 provides a basis for determining the extent to which IRPs may
act hierarchically in mammals.
One example of differential regulation of IRP target mRNAs is
expression of ferritin and eALAS during erythroid differentiation.
Erythroid precursors have a high iron requirement given the large
quantity of heme and hemoglobin they produce. Thus, in erythroid pre-
cursors producing hemoglobin, iron would be diverted tomitochondria
for heme formation and away from storage in ferritin. With regard to
IRPs, the evidence indicates that eALASmRNA ismoreweakly regulated
than ferritin mRNA [9]. In primary murine erythroid progenitors upon
differentiation, ferritin mRNA translation is tightly repressed with less
than 5% of the mRNA polysome bound, whereas translation of eALAS
mRNA is more efﬁciently translated with 40% of this mRNA associated
with polysomes [102]. This 8-fold relative difference in translatability
of these mRNAs occurred under conditions when IRPs are activated
and TfR1 mRNA levels are enhanced. The higher afﬁnity of the ferritin
IRE for IRPsmay in part explain its selective repression under these con-
ditions [103]. It remains to be determined if the polysome bound eALAS
mRNA present during normal erythroid differentiation has escaped IRP
action due to its low-afﬁnity IRE or because variants of the eALASmRNA
exist that lack the IRE. Regarding this point it is of interest that at least
two studies indicate that both IRPs are critical for red cell heme forma-
tion. First, in Irp2−/−mice, eALAS biosynthesis is increased in erythroid
bone marrow precursor cells, leading to inappropriate synthesis of
protoporphyrin IX and anemia [104]. These mice also display reduced
TfR1 and increased ferritin expression, indicating erythroid precursors
are iron deﬁcient. Although Irp1−/− mice do not develop microcytic
anemia, the anemia is more severe in Irp2−/− Irp1+/−mice, indicating
that IRP1 has a role in erythroid function [105]. Second, in zebraﬁsh
and humans, defects in glutaredoxin 5 lead to impairment of mitochon-
drial Fe–S biogenesis and cytosolic iron depletion that activates IRP1,
and reduces eALAS expression [19,43]. Taken together, these studies
suggest that differential targeting of 5′ IRE-containing mRNAs by IRPs
is essential for optimal coordination of heme formation and iron storage
during erythropoiesis.
Another example of differential regulation of IRP target mRNAs is
the expression of ferritin andm-acon [84,106]. Dietary iron deﬁciency
leads to a reduction of liver ferritin to undetectable levels. The decline
of m-acon protein levels under these conditions is signiﬁcant, but
Fig. 4. Altered afﬁnity of IRP1 for mutant and natural IREs. A) The afﬁnity of interaction
of IRP1 for six vertebrate 5′ IREs as determined by electrophoretic mobility shift assays
(EMSA) [108]. The KD for these IREs varied over a 9-fold range. B)Mutations in the human
L-ferritin IREwere identiﬁed in seven patientswith hereditary hyperferritinemia–cataract
syndrome. The afﬁnity of interaction of IRP1 with mutant human L-ferritin IREs was
determined by EMSA and related to serum ferritin values reported for each patient
on different occasions (open circles) [113]. Maximal serum ferritin for each patient (closed
circles). Results on the x-axis are expressed as Krel which is KD,mutant/KD,wildtype and higher
values for Krel indicate lower binding afﬁnity of themutant IREwith IRP1. Note the steeper
slope of the relationship between serum ferritin and Krel over the range 1 to 10 for Krel.
A similar observation was made for IRP2 [113].
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nal, proteins encoded by 5′ IRE-containing mRNAs, are selectively
regulated. These differences in expression can be attributed to the
selective regulation of these proteins at the translational level, as
observed in cultured cells and in cell-free protein synthesis systems
programmed with IRP1 or IRP2 [84,106,107] and the ﬁnding that
IRP1 binds less well to the m-acon versus L-ferritin IRE [108,109].
Consistent with these ﬁndings, genetic ablation of both IRP1 and
IRP2 in mice leads to a substantial enhancement not only of ferritin,
but also ferroportin expression in intestine, while there was a smaller
fold increase in m-acon expression [110]. These studies support the
view that m-acon mRNA is less efﬁciently repressed in tissues com-
pared with other 5′ IRE-containing mRNAs.
A third example of differential regulation of 5′ IRE-containing
mRNAs in mammals comes from a comparison of HIF-2α and L-ferritin
mRNA translation in liver [94]. In iron-replete rat liver, about 3-fold
more HIF-2α mRNA was found associated with polysomes compared
with L-ferritinmRNA. Iron deﬁciency leads to increased IRP RNA binding
activity and a further translational repression of bothmRNAs, yet HIF-2α
mRNA remained more highly polysome associated. Finally, the compar-
ison of succinate dehydrogenase iron protein subunit and ferritin expres-
sion inDrosophila further indicates that IRP hierarchically regulatemRNA
translation in vivo [111]. Thus, differential translational control of 5′ IRE-
containingmRNAby IRPs is essential for adaptive changes in ironmetab-
olism and in other metabolic processes.
What dictates the differential translational control of 5′ IRE-
containing mRNAs? To determine how mRNAs containing functional
5′ IREs are differentially regulated, the afﬁnity of IRP1 for six 5′ IRE-
containing mRNAs was determined [108]. These IREs bound to IRP1 in
a hierarchical manner that related to the function of the encoded pro-
tein, such that ferritin IREs had the highest afﬁnity while m-acon had
the lowest. IRP1 bound to 5′ IREs over a 9-fold range: L-ferritin,
H-ferritin, ferroportin, HIF-2α, eALAS and m-acon (Fig. 4A). Similar re-
sults were reported for IRP1 binding afﬁnities for ferritin and m-acon
IRE using an alternative binding assay [109]. Given the high afﬁnity of
IRP1 for binding the IRE (pM afﬁnity), a valid concern is whether the
9-fold difference in afﬁnity is sufﬁcient to alter regulation. To address
this, the afﬁnity of IRP1 with a L-ferritin mutant IRE observed in a case
of hereditary hyperferritinemia–cataract syndrome (HHCS) was exam-
ined. The afﬁnity of themutant L-ferritin IRE differed from thewildtype
by only 1.9 fold yet this was sufﬁcient to produce L-ferritin dys-
regulation in vivo [108,112]. A more striking evaluation of this is seen
when the afﬁnities of a large number of HHCS IRE mutants were com-
pared to the rise in serum ferritin due to mRNA derepression [113]
(Fig. 4B). The plot of serum ferritin as a function of Krel (relative binding
afﬁnity) revealed that the steepest slope occurred over the ﬁrst 10-fold
loss of afﬁnity. Similar results were obtained for IRP2 [113]. This is
essentially the same range of afﬁnity differences observed for the
binding of natural 5′ IREs to IRP1 (Fig. 4A). These ﬁndings indicate
that small changes in IRP1 or IRP2 binding afﬁnity lead to physiological
and pathologically signiﬁcant changes in the synthesis of proteins
encoded by 5′ IRE-containing mRNAs.
How are these changes in afﬁnity of interaction between IRP1 and
IRE established? Binding afﬁnity is dependent on the number and
strength of bonds between receptor and ligand, and biologically sig-
niﬁcant differences in afﬁnity are usually assumed to involve a loss
or gain of multiple bonds. In the case of IRP1, however, it can be in-
ferred that the 9-fold difference in binding afﬁnity would arise due
to small differences in binding energy equivalent to a single H-bond
[108]. Consequently, Goforth, et al. proposed that the difference in
bond strength and/or in an induced ﬁt mechanism, but not bond
number, may give rise to the regulatory binding hierarchy [108]. In-
deed, the recent report of the crystal structure of IRP1 bound to the
TfR1 B IRE indicated that overall the number of bonds in this complex
was essentially the same as observed in the complex of IRP1 and the
H-ferritin IRE [114]. Thus, subtle differences in binding of IREs to IRPor in the pathway of binding are likely to be an important contributor
to the hierarchical regulation of IRE-containing mRNA. A recent study
reported that the ferritin IRE, but not the m-acon IRE directly
binds ferrous iron, leading to a weakened interaction of IRP1 [109],
suggesting an additional mechanism that contributes to the hierar-
chical regulation of IRE-containing mRNAs. There are also mecha-
nisms to evade IRE action, such as mRNA isoforms that lack the IRE
or those that contain internal ribosome entry sites [78,115].
3.7. What constitutes an IRE?
A key factor in the discovery of the IRE was the strong sequence
identity of a short ~28–30 nt sequence in the 5′ UTR of both H- and
L-ferritin mRNAs. Importantly, the sequence identity between these
IREs (~90%) was substantially greater than that of the coding region
(~50%) amongst vertebrate H- and L-ferritin mRNAs [116]. Of further
signiﬁcance were the accompanying “functional” discoveries of IRPs
and that the IRE conferred iron regulation of translation when trans-
ferred to the 5′ UTR of a heterologous mRNA [117–119]. Shortly
thereafter, multiple IREs were identiﬁed in the 3′ UTR of TfR1 mRNA
where they served to control RNA stability yet could modulate trans-
lation if transferred to a 5′ UTR [120]. The conserved secondary struc-
ture of IREs established the concept that the canonical IRE was an
RNA stem loop with a terminal hexanucleotide CAGUG(N) loop and
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and biochemical studies indicated that formation of the AGU
pseudotriloop, as a consequence of base pairing of the ﬁrst and ﬁfth
nucleotides of the CAGUGN sequence, occurs in solution and is critical
for the binding of IRP1 [122–127]. Molecular and in silico studies
identiﬁed IREs with the same canonical loop sequence and overall
secondary structure in multiple metazoan mRNAs, and demonstrated
key roles of the terminal loop and unpaired C stem in IRP binding
[108,128,129].
The high resolution crystal structures of IRP1 bound to the ferritin
IRE and the TfR1 B IRE provide key insights into the nature of this un-
usually high afﬁnity RNA:protein interaction [114,130] (reviewed in
[128]) (Fig. 6). IRP1 binds to the IRE through two sets of interactions
separated over about 30 Å. IRP1 makes the majority of its bonds with
the IRE in a sequence speciﬁc manner and involves canonical features
of known functional IREs. Thus, the exposed nucleotides, including
AGU of the terminal pseudotriloop and the unpaired C8 residue in the
IRE stem, make 15 of 22 contacts with IRP1. The additional seven
bonds are largely with sites in the phosphodiester backbone of the
IRE stem. The two-site binding mode of IRP1, which bears strong simi-
larities with the recognition of tRNA by tRNA synthetases, allows for
enhanced speciﬁcity of RNA recognition, and likely contributes to the
unusual high afﬁnity of interaction [130]. When bound to IRP1, the
ferritin IRE exhibits signiﬁcant additional bending and twisting of the
RNA helix as a consequence of the larger inter-helical junction around
C8 and due to the presence of the unpaired U6 in ferritin IRE compared
with the TfR1 B IRE. This causes a signiﬁcant difference in the degree to
which the lower stem of the IRE approaches the so-called stem-binding
domain (domain 4) of IRP1 [114] (Fig. 6). Deviations in structure of the
lower stem of IREs have been proposed to make key contributions to
regulation [131].
Signiﬁcant large scale structural changes occur in c-acon, particular-
ly in domains 3 and 4, in order to accommodate the IRE [130] (Fig. 6). In
comparing this structure to that of c-acon [132], Walden et al. provide
unique insight into how structural plasticity of one polypeptide can
support two widely different functions [130]. They proposed that resi-
dues within IRP1/c-acon that inﬂuence the ability to interconvert be-
tween these activities may dictate the ability of why some aconitases
bind RNA but others do not. Importantly, this study establishes a struc-
tural framework from which to evaluate how the different canonical
IREs as well as proposed IRE-like elements may make use of subtleFig. 5. Comparison of the proposed secondary structure of IREs. The key structural
elements required for recognition of the IRE by IRP1 include the unpaired C (C8)
in the IRE stem and the A16G17U18 nucleotides of the pseudotriloop. The canonical
IRE secondary structure is represented by one of the ﬁve TfR1 IREs (TfR1 B), where
the RNA helix is interrupted by only the unpaired C8. The L-ferritin IRE secondary
structure showing the conserved unpaired U at position 6 (arrow). This additional
unpaired nucleotide has been observed in the NMR of the ferritin IRE and the crystal
structure of IRP1 bound to the ferritin IRE [124,130,133]. Proposed secondary structures
of DMT1 and HIF-2α IREs. Note the additional unpaired nucleotides (arrows).
IRE residue numbering is according to Walden et al. [130].differences in bonding or require major differences, possibly including
additional binding partners, in order to allow for their unique regulation
by IRPs.
The ﬁrst indication of structural differences amongst the known IREs
that suggested altered ability to regulatemRNA fate came from studies of
the ferritin IRE [122]. Initial computer predictions had suggested that the
highly conserved unpaired C8 formed a single nucleotide bulge and gave
rise to the canonical view of IRE secondary structure (Fig. 5). However,
secondary structure mapping with small chemical probes conﬁrmed
other in silico predictions of a more complex stem structure compared
to the canonical IREs [103,122,124]. Vertebrate ferritin IREs contain an
unpaired U two base pairs 5′ of C8 (Fig. 5) as conﬁrmed in both NMR
and X-ray crystallography [124,130,133]. This contrasts with all other
known functional IREs and even with ferritin IREs in lower organisms
that appear to only have the single C8 bulge [134]. Interestingly, deletion
of U6 from the ferritin IRE substantially diminishes the afﬁnity of interac-
tion with IRPs, particularly IRP2 [103,108,109,133,135]. Chemical prob-
ing studies suggested that this “double bulge” feature of vertebrate
ferritin IREs is dynamic and may interconvert with a larger UGC/C inter-
nal loop perhaps facilitating direct binding of ferrous iron [103,109].
These additional features likely facilitate structural alterations that may
underlie the stronger regulatory role of the IRE in ferritin relative to
other mRNAs. Indeed, the recent structural studies comparing a single
C-bulge IRE from TfR1 with the H-ferritin IRE bound to IRP1 revealed a
substantial difference in the bend-angle and helical twist of the IRE
stem and the degree to which the lower stem approaches IRP1 [114].
Since these two IREs bind IRP1 with similar afﬁnities [114], it appears
that signiﬁcant plasticity of the RNA and protein allows for the accom-
modation of IREs with different structures. It will be of interest to deter-
mine if alternative structural alterations provide a mechanistic basis for
the substantially weaker binding of the m-acon IRE, and to determine
the impact of unpaired nucleotide(s) in the upper stem, such as observed
for DMT1 and HIF-2α IREs (Fig. 5) [18].
Given the observations that U6 enhances the interaction of both IRPs
with the ferritin IRE, one question is what is the role for bulge nucleo-
tides in other IREs? While structures of IREs other than H-ferritin and
TfR1 B have not been determined, secondary structure predictions sug-
gest that several IREs possess additional unpaired nucleotides in the
stem, especially on the 3′ side (Fig. 5). The HIF-2α and DMT1 each con-
tain a single IRE with an additional 3′ unpaired nucleotide for which
protein expression and RNA binding data are available (Fig. 5). In the
case of both IREs, there is evidence suggesting that they are preferen-
tially regulated by IRP1 [10,11,136]. Given the critical role of hypoxia
in regulating intestinal absorption and erythropoiesis, the possibility
that IRP1 may preferentially regulate these mRNAs is intriguing. A sec-
ond issue of interest concerns whether unpaired nucleotides in differ-
ent IREs program speciﬁc changes in regulation. Deletion of U6 lowers
the afﬁnity of IRP1 for the ferritin IRE and may have an even stronger
effect on IRP2 binding [108,109,133]. In the case of HIF-2α and DMT1
IREs, the impact of the 3′ unpaired nucleotidesmay bias binding toward
IRP1 not IRP2. In addition, the presence of this feature in the HIF-2α and
DMT1 IREs may be critical for limiting the strength of IRP1 binding in
order to ﬁne tune regulation. Finally, a recent transcriptome-wide
examination of mRNAs that interact with IRPs in vitro identiﬁed novel
mRNAs containing canonical IREs, and demonstrated that IRPs may
bind RNAs with differences in the location of unpaired nucleotides or
in upper stem base pairing capacity [18]. Similarly, a recent in silico
study has pointed to additional potential IREs in previously unidentiﬁed
mRNAs [129]. Thus, the reach of the IRP–IRE network may extend into
new areas of cellular function.
3.8. Roles for non-canonical IREs in IRP action
Test-tube RNA evolution experiments (SELEX) provided the ﬁrst
indication of the sequence and structure requirements for IRP recog-
nition of IRE elements [125,126,137,138]. In this regard, one of the
Fig. 6. Crystal structure of c-aconitase and the IRP1:IRE complex. The crystal structures of c-aconitase [132] and the IRP1:IRE complex [121,130] are shown. A) Cytosolic aconitase
structure showing domain 1 (yellow), domain 2 (green), domain 3 (blue) and domain 4 (red) with the [4Fe–4S] cluster in the center (orange balls). B) IRP1:IRE complex structure
shown with domains 1 to 4 as in (A). The ferritin IRE helix (purple) is shown with the two major contact sites of C8 (left) and the A16G17U18 bases of the pseudotriloop shown (right)
as enlarged balls.
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quence was randomized and IRP1 was used to select high afﬁnity
RNA ligands. Intriguingly, an IRE-like RNA was identiﬁed that pos-
sessed a larger terminal loop (CAGUGUCA) along with a somewhat
more complex pattern of unpaired nucleotides in the C8 region of
the stem [138]. On this basis, studies on amyloid precursor protein
(APP) and α-hemoglobin stabilizing protein (AHSPα) mRNAs, and
the recent transcriptome-wide study potentially identifying a wide
array of new IRP targets are of clear interest [18,139,140]. The evidence
strongly suggests that both APP and AHSPα mRNAs are targets of IRP
action. However, the proposed IRE-like element in these mRNA differs
substantially from the canonical IRE, raising questions regarding the
structural basis of their binding to IRP1. It is of interest in this regard
that for the novel RNAs identiﬁed by SELEX that bind tightly to IRP1,
this IRE contains the CAGUGU consensus sequence in a larger eight
nucleotide terminal loop. This IRE is also proposed to have an unpaired
pyrimidine on the 5′ side of the stemwith the correct spacing from the
critical AGU binding site in the terminal loop. In contrast, the APP and
AHSPα IRE-like elements do not have these structural elements. Thus,
while the evidence is strong that IRP1 associates with APP and AHSPα
mRNAs in cells, the question as to whether IRP1 binds these elements
indirectly or whether they require the assistance of protein partners re-
mains to be determined. The recent transcriptome-wide analysis [18]
suggested that IRPsmay bindmanynon-canonical IRE RNAs, suggesting
the presence of an expanded IRP-dependent post-transcriptional
regulon.
4. Recent advances in IRP2 regulation
The last decade has seen major advances in IRP2 regulation. The
identity of FBXL5 as the E3 ligase responsible for the iron-mediated
degradation of IRP2 was discovered. New insights into the role of
IRP2 in cell proliferation have been deﬁned, and mouse models of
IRP2 deﬁciency have provided mechanistic insight into its role in
regulating cellular iron homeostasis.
4.1. Iron-mediated regulation of IRP2 stability
IRP2 is primarily regulated by protein stability: iron depletion and
hypoxia stabilize IRP2, whereas iron promotes IRP2 ubiquitination
and proteasomal degradation [141–144]. One early study reported
that a cysteine rich 73-amino acid domain was required for iron-
mediated degradation of IRP2 [144]. Several models were proposed
whereby iron or heme oxidized speciﬁc cysteine residue(s) within
the 73-amino acid domain, triggering the ubiquitination and degrada-
tion of IRP2 [145,146]. A protein designated heme-oxidized IRP2 Ub
ligase (HOIL-1) was identiﬁed and shown to bind to heme-oxidizedresidues within the 73-amino acid domain [147,148]. Subsequent
studies from several groups showed that mutation of cysteine resi-
dues within the 73-amino acid domain or deletion of the entire 73-
amino acid domain did not affect iron-mediated degradation of IRP2
[149–151]. Furthermore, HOIL-1 silencing or overexpression in cul-
tured cells had no effect on the degradation of IRP2 by iron [152].
These studies prompted investigation into other mechanisms to ac-
count for IRP2 degradation by iron.
Recently, a novel E3 ligase complex, SKP1–CUL1–FBXL5, was iden-
tiﬁed as the E3 ligase responsible for iron-mediated IRP2 degradation
[89,90] (Fig. 7). FBXL5 was independently identiﬁed by two groups
using different approaches. Vashisht et al. [90] used multidimensional
protein identiﬁcation technology (MUDPIT) to identify proteins that
interact with epitope-tagged FBXL5. Salahudeen et al. [89] used a
small interfering RNA (siRNA) screen to identify proteins that altered
IRP2 degradation. FBXL5 is a member of the F-box family of adaptor
proteins that confer substrate speciﬁcity to SCF E3 Ub ligases
(reviewed in [153,154]). FBXL5 is conserved in vertebrates, and con-
tains an N-terminal hemerythin domain, a F-box domain that medi-
ates its association with SKP1 and four leucine-rich repeats that
likely function in IRP2 binding. Hemerythrins are oxygen carrier pro-
teins in marine organisms that bind to oxygen through a diiron L cen-
ter [155]. Hemerythrin-like domains have been identiﬁed in bacterial
proteins where they are thought to function as oxygen sensors
[156,157]. FBXL5 represents the ﬁrst eukaryotic protein to contain
this domain.
Several experiments showed that FBXL5 regulates IRP2 stability
[89,90,158]. First, FBXL5 forms a SCF complex that interacts with IRP2
in vitro. The region of IRP2 that binds FBXL5 is not yet known, but the
73-amino acid domain is not involved. A study showed that sequences
in the C-terminal region of IRP2 are necessary, but not sufﬁcient for
IRP2 degradation [159]. Because IRP1 is a FBXL5 substrate, it is likely
that IRP1 and IRP2 share a similar degron. Second, FBXL5 silencing
stabilized IRP2,whereas FBXL5overexpression promoted IRP2 degrada-
tion. Third, FBXL5 is stabilized in iron-replete cells, and destabilized by
iron depletion and hypoxia. The hemerythrin domain is required for
FBXL5 stability asmutations in speciﬁc histidine and glutamate residues
within this domain reduced FBXL5 abundance and iron-dependent
stability. Finally, reduced stability of FBXL5 during iron depletion or
hypoxia provides an explanation for IRP2 accumulation during hypoxia
[150,160,161]. Similarly, the enhanced degradation of IRP2 by antioxi-
dants and stabilization of IRP2 by oxidants is also likely explained by
changes in FBXL5 stability [88,161]. It should be noted that oxidative
stress can also inactivate IRP2 RNA binding independent of changes
in IRP2 protein levels [162–164], and in one study this was shown to
be due to oxidation of cysteines that are predicted to lie in the RNA-
binding cleft [164].
Fig. 7. Mechanisms for iron-dependent and iron-independent IRP2 regulation. Iron-dependent degradation: when iron and oxygen are high, the FBXL5 hemerythrin-domain binds
iron and leads to a conformational change that increases FBXL5 stability. FBXL5 binds to IRP2 and FBXL5-IRP2 associates with SKP1–CUL1 complex, catalyzing the ubiquitination and
proteasomal degradation of IRP2. When iron or oxygen is limited, FBXL5 is destabilized and targeted for degradation by an unidentiﬁed E3 ligase. IRP2 iron-independent pathway:
IRP2 is phosphorylated by cyclin-dependent kinase 1 (CDK1/cyclinB1) during G2/M and dephosphorylated by CDC14A at the end of mitosis. S157 phosphorylation is independent of
iron and is associated with reduced RNA binding activity. Non-phosphorylated and phosphorylated IRP2 are subjected to FBXL5 iron-mediated degradation.
Modiﬁed from Wallander et al. [4].
1476 C.P. Anderson et al. / Biochimica et Biophysica Acta 1823 (2012) 1468–1483Structural analysis revealed that the FBXL5 hemerythrin domain
adopts a hemerythrin-like alpha-helical bundle fold stabilized by a
diiron center [158] [see also Bruick et al. in this volume]. Although
many hemerythrins can reversibly bind oxygen at the diiron center,
there was no evidence for oxygen binding to the FBXL5 hemerythrin
domain. A current model for FBXL5 regulation of IRP2 proposes that
in the presence of iron and oxygen, the hemerythrin domain binds
iron, leading to the stabilization of a FBXL5 E3 ligase that catalyzes
IRP2 ubiquitination and proteasomal degradation (Fig. 7). Iron deple-
tion or hypoxia causes a conformational change in FBXL5 rendering
it susceptible to proteasomal degradation by an unidentiﬁed E3
ligase. How oxygen contributes to FBXL5 iron binding remains to be
determined.
Several other mechanisms have been proposed to regulate iron-
mediated degradation of IRP2. One mechanism involves 2-oxoglutarate
(2-OG) dependent dioxygenases, which are enzymes that catalyze the
hydroxylation of protein substrates (reviewed in [165]). These enzymes
require iron, oxygen and 2-OG for catalysis. A notable example of 2-OG
dioxygenase activity is the proline hydroxylation of HIF‐α subunits
during normoxia by prolyl-hydroxylases, targeting HIF-α subunits for
ubiquitination and proteasomal degradation by the von Hippel–Lindau
E3 ligase (reviewed in [96]). Evidence for 2-OG dependent dioxygenases
in IRP2 degradation comes from studies showing that the 2-OG depen-
dent dioxygenase inhibitor, dimethyloxalylglycine, blocked IRP2 degra-
dation by iron [150,151]. Heme has been shown to have a role in
IRP2 iron-mediated degradation as the heme biosynthesis inhibitor,
succinylacetone, partially stabilized IRP2 against iron degradation
[73,149,166]. A calcium dependent non-proteasomal pathway has
been reported to regulate the steady-state abundance of IRP2 during
iron replete conditions [167]. This pathway was only operative in spe-
ciﬁc cell lines, and was proposed as a mechanism to limit IRP2 abun-
dance during normal growth conditions. Lysosomal degradation of
IRP2 has also been reported [168]. IRP2 was stabilized in cells treated
with the lysosomal inhibitors ammonium chloride and chloroquine.
IRP2was found to be degraded by lysosomes only under normal growth
conditions (for example, in the absence of added iron), while iron
overload resulted in IRP2 degradation by the proteasome. A caveat
is that lysosomal inhibitors increase lysosomal and endosomal pH,
and can cause cellular iron deﬁciency by inhibiting iron release from
transferrin [169]. In this scenario, FBXL5 would be destabilized, leadingto increased IRP2 abundance. As the aforementioned studies relied on
the use of pharmacological inhibitors to inhibit 2-OG-dependent
dioxygenases, heme biosynthesis, proteasomal and lysosomal func-
tions, experiments using alternative approaches are needed to corrobo-
rate these mechanisms.4.2. IRP2 and cell proliferation
Iron is critical for growth of tumors (reviewed in [170]). As a re-
sult, many tumor cells satisfy their increased need for iron by increas-
ing TfR1 expression as well as reducing ferritin and ferroportin
expression [171–175]. Changes in iron uptake, sequestration and ex-
port provide mechanisms to increase cellular iron for proliferative
processes. IRP2 has also been shown to have a role in cell proliferation.
IRP2 overexpression in H1299 lung cancer cells stimulated their ability
to form tumors when grown as xenografts in immunodeﬁcient mice,
whereas overexpression of IRP2 lacking the 73-amino acid domain
suppressed tumor xenograft growth, suggesting a unique function for
this domain [176]. By contrast, overexpression of IRP1 in H1299 lung
cancer cells suppressed tumor xenograft growth in mice [177]. Surpris-
ingly, both IRP1 and IRP2 expressing xenografts displayed elevated TfR1
levels, but IRE target mRNAs, such as ferritin and ferroportin, were not
affected. c-MYC and phospho-ERK1/2 levels were elevated in IRP2-
expressing tumors compared to tumors expressing IRP2 lacking the
73-amino acid domain. These studies raise the possibility that uni-
dentiﬁed IRP-target mRNAs are involved in cell proliferation and/or
that IRPs have roles in cell proliferation unrelated to their function as
RNA binding proteins.
Another study showed that IRP2 is phosphorylated on Ser157
located within the 73-amino acid domain. IRP2 is phosphorylated
by cyclin-dependent kinase 1 (Cdk1/cyclin B1) during G2/M and
dephosphorylated by the phosphatase CDC14A during mitotic exit
[178] (Fig. 7). S157 phosphorylation is not dependent on iron and is as-
sociated with reduced IRP2 RNA binding during G2/M as evidenced by
increased ferritin synthesis. It is interesting to note that CDC14A
mRNA harbors a 3′ IRE; however, regulation of CDC14A mRNA was
not associated with Ser157 phosphorylation during the cell cycle. How
IRP2 Ser157 contributes to cell cycle regulation and proliferation
remains to be determined.
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in mice
Over the past decade, the generation of global and conditional
mouse models of IRP2 and IRP2/IRP1 deﬁciency has demonstrated
their importance in cellular iron metabolism. These studies have
also underscored their critical role in mitochondrial iron metabolism.
5.1. Total body ablation of IRP1 and IRP2
Genetic inactivation of both Irp1 and Irp2 in mice leads to embry-
onic lethality at the blastocyst stage indicating a critical role for the
IRP–IRE network during early development [110,179,180]. Irp1−/−
mice lack an overt phenotype, despite mild ferritin dysregulation in
kidneys and in brown fat [179]. The lack of an overt phenotype is sur-
prising as c-acon is a highly conserved protein found in many diverse
organisms and that c-aconitase is the principal form present in tissues
of the body [160]. The function of c-acon is still not well understood,
but apparently it is not required for normal physiology.
Two distinct strains of Irp2−/−mice have been generated. One strain
was generated by the insertion of a PGK-neomycin gene into exon 3/4
of the Irp2 gene [181] and the other strain was generated by Cre–Lox
technology [182]. Both Irp2−/− mouse strains develop mild microcytic
anemia and altered body iron distribution [104,183]. Iron content is
elevated in intestine and liver and is associated with increased ferritin
expression and decreased TfR1 expression, and is reduced in splenic
macrophages and is associated with decreased ferritin expression.
Microcytic anemia in Irp2−/− mice is associated with normal
transferrin saturation and serum iron parameters, and is thought to
be due to cellular iron deﬁciency in erythroid precursors as a conse-
quence of reduced TfR1 levels and increased ferritin levels [104,183].
Because erythroid precursors are dependent on transferrin-bound iron
for heme synthesis, increased iron sequestration in ferritin and reduced
iron uptake would lead to a reduction in the cellular labile iron pool,
impairing heme synthesis. Mice lacking IRP2 in enterocytes, hepato-
cytes or macrophages do not develop microcytic anemia suggesting
that microcytic anemia in Irp2−/− mice is an intrinsic defect of iron
homeostasis in erythroid precursors [184]. Irp2−/− mice also develop
erythropoietic protoporphyria characterized by increased proto-
porphryin IX in bone marrow, serum and liver [104]. Erythroid ALAS
synthesis is upregulated in Irp2−/− erythroid precursors likely due to
loss of IRP2 translational repression. The heme precursor protoporphy-
rin IX accumulates in erythroid precursors due to reduced iron availabil-
ity required to complete heme synthesis.
The Irp2−/− strain generated by LaVaute et al. [181] develop a late
onset neurodegenerative disorder characterized by abnormal gait,
hind-limb weakness and tremors, and by reduced grooming and neu-
romuscular performance assayed by the hanging wire test. The cere-
bellum, substantia nigra, hippocampus and caudate putamen among
other brains areas displayed elevated levels of ferric iron and ferritin
that correlated with axonopathy and neuronal loss [105]. The onset
and severity of neurodegeneration is exacerbated in Irp2−/− Irp1+/−
mice, demonstrating a gene dosage effect with the IRPs [75,105]. Neu-
rodegenerative symptoms in both Irp2−/− and Irp2−/− Irp1+/− mice
were alleviated by Tempol, a membrane-permeable radical scaven-
ger, where it reduced ferritin levels and lower iron content in cerebel-
lar white matter tracts [75]. Tempol was shown to convert the c-acon
form of IRP1 to the RNA binding form that stabilized TfR1 mRNA and
repressed ferritin synthesis, and thus restored iron homeostasis. More
recently, Irp2−/− mice were reported to have lower motor neuronal
degeneration and spinal cord axonopathy that was more severe in
Irp2−/−Irp1+/− [185]. Lumbar spinal sections in Irp2−/−mice showed
the accumulation of myelin dense bodies, which are hallmarks of neu-
rodegeneration, in the ventral and lateral white matter. Mitochondria
in the lumbar spinal cord were swollen, and displayed disrupted
and vacuolized cristae. Ferritin and TfR1 levels were increased anddecreased, respectively, in motor neurons, and total iron content was
reduced in the spinal cord, consistent with cellular iron deﬁciency in
motor neurons of Irp2−/−mice. Respiratory complexes I and II activities
were reduced in lumbar spine mitochondria in Irp2−/− mice. As com-
plexes I and II contain Fe–S clusters and heme prosthetic groups essen-
tial for activity, this suggested that cellular iron deﬁciency in motor
neurons might impair mitochondrial function, leading to neuronal de-
generation. This hypothesis was tested by treating Irp2−/− mice with
Tempol and by crossing Irp2−/− or Irp2−/−Irp1+/− mice into a Fth−/+
background [186]. Motor neuron survival improved using both ap-
proaches consistent with the notion that cellular iron deﬁciency has a
role in motor neuronal degeneration in Irp2−/−mice.
In contrast to Irp2−/− mice generated by LaVaute et al. [181],
Irp2−/− mice generated by Galy et al. [187] did not display an abnor-
mal gait, hind-limb weakness and tremors or neuropathological
changes at 13–14 months of age. Perls' and TUNEL staining did not re-
veal signs of iron deposition or cellular degeneration in the brain, and
electron microscopy showed no evidence of ultrastructural defects or
mitochondriopathy. Irp2−/−mice also did not show impaired muscle
strength when tested by the forepaw grip strength test (analogous to
the hanging wire test used by LaVaute et al. [181]). In agreement with
LaVaute et al. [181], the Irp2−/− strain generated by Galy et al. [187]
displayed motor coordination and balance defects and reduced
grooming activity when assayed by the rotarod and the modiﬁed-hole
board tests. In addition, both strains displayed decreased TfR1 and
increased ferritin expression in the brain [187]. Whether differences
in severity of clinical and pathological signs of neurodegeneration be-
tween the two Irp2−/− strains are due to targeting strategies, genetic
backgrounds or technical issues is not known.
5.2. Macrophage/monocyte ablation of IRPs
Splenic and bone marrow macrophages of Irp2−/− mice have re-
duced ferric iron stores with repressed levels of ferritin and ferroportin
[104,183,184]. Interestingly, these mice have a slight increase in serum
ferritin and normal hepcidin levels [104,183,184]. Ferritin secretion en-
sues when cellular ferritin synthesis occurs during iron depletion, and
may explain reduced ferritin levels and splenic iron deposition seen in
these animals [188]. A conditional deletion of IRP2 from macrophages/
monocytes using LysozymeM-Cre did not recapitulate the splenic phe-
notype seen in Irp2−/− mice [184], suggesting that splenic iron mis-
management may be a result of IRP2 deﬁciency in another cell type or
the combined effect of IRP2 deﬁciency in multiple tissues.
5.3. Intestinal ablation of IRPs
The function of IRPs in iron absorption was investigated by speciﬁc
deletion of IRP2 alone or both IRP1 and IRP2 in intestinal epithelial
cells [184]. Mice lacking IRP2 in the duodenum recapitulated the
intestinal phenotype of duodenal iron loading and increased ferritin
expression in Irp2−/− mice. Duodenal iron content and ferritin levels
were not affected in mice lacking IRP2 in hepatocytes or in macro-
phages, suggesting that dysregulated iron homeostasis in IRP2 deﬁ-
cient duodenum is likely cell autonomous.
Mice lacking both IRP1 and IRP2 in intestinal epithelial cells were
generated by breeding mice homozygous for ﬂoxed Aco1 and Ire2
alleleswithmice expressing Cre-recombinase under control of theVillin
promoter [110]. These mice displayed severe growth defects 7 days
post-partum, and 80% of the animals died shortly after weaning likely
due to dehydration, with the remaining 20% reaching adulthood due to
incomplete IRP deletion. IRP deﬁcient enterocytes from mice displayed
less structured duodenal crypts and villi, and intestinal enterocytes
exhibited mitochondriopathy along with increased apoptosis. Ferritin
and ferroportin levels were profoundly increased, and TfR1 and DMT1-
IRE isoform mRNAs and protein were decreased. The increase in
ferroportin levels occurred without changes in mRNA levels and despite
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accounted by increased hepatic iron loading, and was postulated to be
due to decreased erythropoiesis or inﬂammation. Surprisingly, blood
parameters revealed no signs of systemic iron defects given the profound
changes in cellular iron homeostasis in mice with IRP deﬁcient
enterocytes. It is possible that increased iron export by ferroportin equal-
izes reduced iron uptake and increased iron sequestration in ferritin. This
study demonstrated that dysregulation of iron uptake, storage and
export in IRP deﬁcient enterocytes is consistentwith cellular iron starva-
tion as a possible cause for mitochondriopathy and impaired enterocyte
function.
The importance of ferritin in iron absorption was demonstrated in
micewith a speciﬁc deletion of H-ferritin subunit in intestinal epithelial
cells [189]. Thesemice showed increased body iron stores and transfer-
rin saturation, and as expected, increased hepatic hepcidin mRNA
levels. Further analysis showed reduced levels of DMT1, DYCTB and
TfR1 mRNAs, while ferroportin and L-ferritin subunit increased. IRP2
levels were reduced, suggesting an increase in the cellular labile iron
pool, which would lead to the destabilization of DMT1 and TfR1
mRNAs and increased synthesis of ferroportin and L‐ferritin subunit.
DMT1 and DCYTB mRNAs are transcriptionally activated by HIF-2α in
iron-deﬁcient mice [98,99]. Whether reduced DMT1 and DCYTB
mRNAs in H-ferritin deﬁcient enterocytes are in part due to reduced
HIF-2α accumulation is not known.5.4. Hepatic ablation of IRPs
Conditional deletion of IRP2 in hepatocytes recapitulated the
hepatic phenotype in Irp2−/− mice where iron loading was associated
with ferritin derepression. In these mice, expression of TfR1 and
DMT1 was unchanged, and the mechanism for increased hepatic iron
loading is not clear. Mice lacking IRP2 in enterocytes or macrophages
showed no evidence of iron loading in hepatocytes, showing that
dysregulated iron homeostasis in hepatocytes in IRP2 deﬁcient mice
is intrinsic to hepatocytes.
The deletion of both IRP1 and IRP2 in hepatocytes has provided
insight into IRP function in vivo [190]. Hepatocyte IRP deﬁciency causes
mice to die between 8 and 12 days post-partum. Profound liver damage
as characterized by internal bleeding, hepatic steatosis and increased
apoptosis was apparent in these animals. Despite reduced hepcidin
levels, there were no overt signs of systemic iron dysfunction. Analysis
of IRP-target mRNAs showed that levels of ferritin and ferroportin
were elevated, whereas levels of TfR1 and the DMT1-IRE mRNAs
and protein are decreased. Zip14 (SLC39A14, iron transporter) and
mitoferrin 2 (SLC25A28, mitochondrial iron transporter), which are
not IRP regulated, were also downregulated. Total liver nonheme iron
and mitochondrial nonheme iron were reduced 50% compared with
control mice. The reduction in iron uptake coupled with increased
iron sequestration in ferritin and increased iron export by ferroportin
is consistent with severe cellular iron starvation in IRP deﬁcient
hepatocytes.
Mitochondrial dysfunction is a deﬁning feature of many fatty liver
diseases [191]. Consistent with this, mitochondriopathy is the major
pathological consequence of hepatocyte IRP deﬁciency [190]. Mito-
chondria appear swollen, and contain hypodense matrices and abnor-
mal cristae architecture, consistent with iron and copper deﬁciency in
rodents [192]. Interestingly, the expression of the mitochondrial iron
transporter mitoferrin 2 is reduced in IRP deﬁcient hepatocytes and
correlates with a reduction in mitochondrial nonheme iron. Mito-
chondria are responsible for the synthesis of Fe–S clusters and heme
that are required by complexes I, II and III and by TCA cycle enzymes.
IRP deﬁcient hepatocytes display markedly reduced activities of
complexes I, II and III and ferrochelatase, as well as the cytosolic Fe–S
cluster containing protein xanthine dehydrogenase. It is likely that
defects in the electron transport chain and TCA cycle are majorcontributing factors to the mitochondrial abnormalities seen in IRP
deﬁcient hepatocytes.
5.5. Mouse models of FBXL5 and FBXL5-IRP2 deﬁciencies
The importance of IRP2 in cellular iron metabolism was further
highlighted by FBXL5 ablation in mice [91]. Total body ablation of
FBXL5 inmice resulted in embryonic lethality at E8.5, andwas associated
with iron overload and oxidative stress in embryos. Embryonic lethality
was prevented by simultaneous ablation of IRP2. Fbxl5−/−Irp2−/− mice
developed normally and were physically indistinguishable from lit-
termate controls. Mice with hepatocyte speciﬁc ablation of FBXL5
were viable, but developed hepatic steatosis and mitochondriopathy
in hepatocytes. Increased IRP levels were associated with increased
TfR1 levels and ferrous iron in hepatocytes. Unexpectedly, L-ferritin
protein and mRNA levels increased in FBXL5 deﬁcient hepatocytes
compared with control mice despite increased IRP expression. The
most likely explanation for increased ferritin expression is transcrip-
tional activation of the L-ferritin gene induced by oxidative stress in
hepatocytes [193]. Mice lacking hepatocyte FBXL5 displayed reduced
hepcidin mRNA expression as a consequence of reduced BMP signal-
ing. These mice also showed reduced survival when fed a high iron
diet. Taken together, this study showed that embryonic lethality in
Fbxl5−/−mice is primarily due to dysregulation of IRP2 degradation,
which leads to increased cellular iron and oxidative stress, and show
that FBXL5 regulation of IRP2 is critical for regulation of cellular iron
homeostasis.
5.6. IRP–IRE network in human disease
To date there are no reports of mutations in IRP1 or IRP2 that cause
human disease, but mutations in IREs or in coding sequences of IRE-
encoded genes have been linked to human disorders. Mutations in
L‐ferritin subunit mRNA cause autosomal dominant hereditary
hyperferritinemia–cataract syndrome (HHCS) that is characterized by
juvenile bilateral cataracts and high levels of serum ferritin without
iron overload. These mutations reduce IRP binding to the 5′ IRE and
lead to abnormal L‐ferritin subunit accumulation in tissues and serum
[194–196]. A point mutation in the 5′ IRE of H‐ferritin subunit that
increases its afﬁnity for IRPs causes autosomal dominant iron overload
disorder [197]. Coding region mutations in L‐ferritin subunit cause he-
reditary ferritinopathy or neuroferritinopathy characterized by abnor-
mal ferritin inclusion aggregates and iron in the globus pallidus [198].
These mutations alter the amino acid sequence at the C-terminus of
L-ferritin subunit, reducing its stability and ability to incorporate iron
[199,200]. The neurodegeneration and iron overload phenotype was
replicated in mice expressing a mutant L-ferritin subunit form [201]. A
missense mutation in the L‐ferritin subunit coding sequence was iden-
tiﬁed that leads to high levels of serum ferritin without iron overload
[202]. Kannengiesser and colleagues [188] postulated that thismutation
may modify a signal sequence that increases secretion of L‐ferritin sub-
units, and a subsequent study in cell culture shows that secretion of this
mutant ferritin is increased as compared to wildtype ferritin [188]. Mu-
tations have been reported in other IRE-encoded genes, such as eALAS
(sideroblastic anemia) [203–205], ferroportin (hereditary hemochro-
matosis) [206,207] and DMT1 [208–210]. These studies show that
abnormal expression of proteins encoded by IRE-containing mRNAs
disrupts systematic and cellular ironmetabolism and leads to iron over-
load and neurodegeneration.
A genome wide association study (GWAS) has associated various
IRP2 polymorphisms with Alzheimer's disease (AD) [211]. A poten-
tially functional single nucleotide polymorphism (SNP) in the IRP2
promoter region was located within a consensus binding site for the
AP-1 and SP1 transcription factors, and could possibly explain altered
IRP2 expression seen in AD patients. This is of interest as a study
showed IRP2 co-localization with pathological features of AD, including
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tween IRP2 and neurodegenerative disease involves the regulation of
amyloid precursor protein (APP). Studies have shown APP to be a func-
tional ferroxidase that interacts with FPN in mediating iron export,
and inhibition of ferroxidase activity leads to neuronal iron accumu-
lation consistent with AD [213]. Similarly, neurons of Tau deﬁcient
mice retain iron and mislocalize APP, thus disrupting iron export by
FPN [214]. More importantly, iron chelation with Clioquinol alleviated
cognitive deﬁcits seen in these Tau deﬁcient mice. These observations
highlight the importance of iron metabolism in maintaining proper
neurological function, and provide therapeutic opportunities for treating
neurodegenerative diseases such as Alzheimer's and Parkinson's. More
recent GWAS have found strong associations between IRP2 and patients
with chronic obstructive pulmonary disease (COPD) [215]. Three SNPs
in IRP2 were found to correlate with reduced forced expiratory volume
(FEV), a prominent feature of COPD [216]. It is known that IRP2 expres-
sion is altered in lung tissue from COPD patients, and iron deposition is
increased in the lungs of smokers [215]. Further studies are needed to
conﬁrm a role for IRP2 in AD and COPD.
6. Outlook
Since their discovery over 20 years ago, IRPs still remain an active
ﬁeld of research. Iron-dependent and iron-independent mechanisms
regulating IRP1 and IRP2 function have been identiﬁed and the physio-
logical consequences of these mechanisms determined. The crystal
structure of IRP1 bound to RNA has provided a basis to study the selec-
tivity of IRE binding. Mouse models of IRP deﬁciency have shown the
importance of IRPs in regulating cellular iron metabolism. The elusive
E3 ligase mediating IRP2 degradation by iron has been identiﬁed, and
the identiﬁcation of novel IREs has broadened our vision of the IRP–
IRE network.
At a mechanistic level, many questions regarding IRP function re-
main unanswered. One question regards the pathways of Fe–S cluster
biogenesis that are directly sensed by IRPs and whether trafﬁcking of
iron through mitochondria is an obligate process through which IRPs
sense iron. Additionally, the extent to which Fe–S cluster removal
from c-acon versus de novo synthesis of IRP1 contribute to its role in
homeostatic regulation of iron in animals needs attention. Another
question is to determine how canonical and non-canonical IREs bind
IRP1 to allow for their linkage to processes uniquely sensed by IRP1
(e.g. cytosolic Fe–S biogenesis). The discovery of novel IREs that prefer-
entially bind to IRP1 or IRP2 is an opportunity to study links between
iron homeostasis and other cellular or organismal processes. For exam-
ple, what is the physiological signiﬁcance of the preferential regulation
of HIF-2α IRE by IRP1? The identiﬁcation of FBXL5 E3 ligase raises the
question whether other substrates are also targeted by FBXL5. The
role of the IRP2 73-amino acid domain and Ser157 phosphorylation in
cell proliferation requires further investigation. A better understanding
of how iron contributes to neurodegeneration is neededwith the goal of
developing safer and effective therapies to treat these disorders.
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